The share capital of IGEA Pharma N.V. comprises 25,048,769 shares with a nominal value of EUR 0.01 each. The opening price was CHF 3.75 per share, corresponding to a market capitalization of around CHF 94 million. An offering of the company’s shares has not taken place.

IGEA Pharma N.V. is a life sciences company with its corporate headquarters in Amsterdam in the Netherlands. The IGEA Group focuses on products and services related to the prevention of Alzheimer's and Type II Diabetes. For more information on the company, please visit: www.igeapharma.nl


Any questions?

If you have any questions, please do not hesitate to contact Julian Chan, Media Relations.

 
SIX
SIX operates and develops infrastructure services in the Securities & Exchanges, Banking Services and Financial Information business units with the aim of raising efficiency, quality and innovative capacity across the entire value chain of the Swiss financial center. The company is owned by its users (127 banks). With a workforce of some 2,600 employees and a presence in 20 countries, it generated operating income in excess of CHF 1.9 billion and Group net profit of CHF 221.3 million in 2018.
www.six-group.com